This page was translated automatically from Turkish. Read the original

Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun.

Understanding stakeholder priorities in depression treatment: point allocation findings from two cognitive behavioural therapy trials

Understanding stakeholder priorites in depression treatement: point allocation findings from two cbt trials

Service users and clinicians consider depressive symptoms, quality of life, anxiety symptoms, and the impact on daily activities to be similarly important.

The aim was to examine how stakeholders prioritise outcome domains, investigate differences between groups, and identify factors predicting domain importance, in light of evidence that service users and clinicians value a broader range of benefits, although outcome selection in depression trials tends to focus on symptom reduction. Drawing on two completed cognitive behavioural therapy (CBT) trials in the United Kingdom, participants completed an online survey that included a point allocation task in which they distributed importance points across outcome domains; free-text explanations were analysed thematically, between-group differences were assessed using multivariate analysis of covariance (MANCOVA), and sociodemographic predictors were examined using exploratory multivariate general linear models. A total of 229 people participated (57 service users with minimal symptoms, 108 service users with current depressive symptoms, and 64 clinicians). Median point allocations indicated that all groups attached similar importance to depressive symptoms, quality of life, anxiety symptoms, and the impact on daily activities; in the currently symptomatic group, sociodemographic characteristics predicted domain importance, with age emerging as a consistent factor. In conclusion, although symptom improvement remains important, stakeholders consider it alongside broader outcomes, such as quality of life, that are rarely used as measures of benefit in depression trials; incorporating domains that matter to stakeholders into outcome selection and allowing these priorities to guide the development of composite outcome measures may support the evaluation of treatment benefits from stakeholders’ perspectives.

Tüm WCP 2026 özetleri